Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma

The clinical deployment of immune checkpoint inhibitors (ICIs) has created a tandem drive for the identification of biomarkers linked to benefit. Comprehensive genomic profiling was performed to evaluate the frequency of genomic biomarkers of ICI response in 755 patients with advanced hepatocellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, Celina, Klempner, Samuel J., Ali, Siraj M., Madison, Russell, Ross, Jeffrey S., Severson, Eric A., Fabrizio, David, Goodman, Aaron, Kurzrock, Razelle, Suh, James, Millis, Sherri Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592287/
https://www.ncbi.nlm.nih.gov/pubmed/31258846
http://dx.doi.org/10.18632/oncotarget.26998

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592287/
https://www.ncbi.nlm.nih.gov/pubmed/31258846
http://dx.doi.org/10.18632/oncotarget.26998

Ejemplares similares